AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease

Abraham Fisher, Ilya Bezprozvanny, Lili Wu, Daniel A. Ryskamp, Nira Bar-Ner, Niva Natan, Rachel Brandeis, Hanoch Elkon, Victoria Nahum, Eitan Gershonov, Frank M. LaFerla, Rodrigo Medeiros

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ40, Aβ42, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)95-110
Number of pages16
JournalNeurodegenerative Diseases
Volume16
Issue number1-2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Muscarinic M1 Receptors
Nootropic Agents
Alzheimer Disease
Animal Models
Trihexyphenidyl
Pathology
Muscarinic Agonists
Agaricales
Carbachol
Amyloid
Synapses
Cholinergic Agents
Water
Therapeutics
(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one
cevimeline
Cognitive Dysfunction
AF710 compound

Keywords

  • AF series
  • AF267B
  • AF710B
  • Alzheimer's disease
  • Amyloids
  • Cognitive deficits
  • Disease modification
  • M1 muscarinic acetylcholine receptor
  • Memory
  • Neuroinflammation
  • Tau protein
  • σ1 receptor

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. / Fisher, Abraham; Bezprozvanny, Ilya; Wu, Lili; Ryskamp, Daniel A.; Bar-Ner, Nira; Natan, Niva; Brandeis, Rachel; Elkon, Hanoch; Nahum, Victoria; Gershonov, Eitan; LaFerla, Frank M.; Medeiros, Rodrigo.

In: Neurodegenerative Diseases, Vol. 16, No. 1-2, 01.02.2016, p. 95-110.

Research output: Contribution to journalArticle

Fisher, A, Bezprozvanny, I, Wu, L, Ryskamp, DA, Bar-Ner, N, Natan, N, Brandeis, R, Elkon, H, Nahum, V, Gershonov, E, LaFerla, FM & Medeiros, R 2016, 'AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease', Neurodegenerative Diseases, vol. 16, no. 1-2, pp. 95-110. https://doi.org/10.1159/000440864
Fisher, Abraham ; Bezprozvanny, Ilya ; Wu, Lili ; Ryskamp, Daniel A. ; Bar-Ner, Nira ; Natan, Niva ; Brandeis, Rachel ; Elkon, Hanoch ; Nahum, Victoria ; Gershonov, Eitan ; LaFerla, Frank M. ; Medeiros, Rodrigo. / AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. In: Neurodegenerative Diseases. 2016 ; Vol. 16, No. 1-2. pp. 95-110.
@article{ce9981fb0ff1484cb20617a981a2eb7e,
title = "AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease",
abstract = "We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ40, Aβ42, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.",
keywords = "AF series, AF267B, AF710B, Alzheimer's disease, Amyloids, Cognitive deficits, Disease modification, M1 muscarinic acetylcholine receptor, Memory, Neuroinflammation, Tau protein, σ1 receptor",
author = "Abraham Fisher and Ilya Bezprozvanny and Lili Wu and Ryskamp, {Daniel A.} and Nira Bar-Ner and Niva Natan and Rachel Brandeis and Hanoch Elkon and Victoria Nahum and Eitan Gershonov and LaFerla, {Frank M.} and Rodrigo Medeiros",
year = "2016",
month = "2",
day = "1",
doi = "10.1159/000440864",
language = "English (US)",
volume = "16",
pages = "95--110",
journal = "Neurodegenerative Diseases",
issn = "1660-2854",
publisher = "S. Karger AG",
number = "1-2",

}

TY - JOUR

T1 - AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease

AU - Fisher, Abraham

AU - Bezprozvanny, Ilya

AU - Wu, Lili

AU - Ryskamp, Daniel A.

AU - Bar-Ner, Nira

AU - Natan, Niva

AU - Brandeis, Rachel

AU - Elkon, Hanoch

AU - Nahum, Victoria

AU - Gershonov, Eitan

AU - LaFerla, Frank M.

AU - Medeiros, Rodrigo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ40, Aβ42, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.

AB - We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ40, Aβ42, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.

KW - AF series

KW - AF267B

KW - AF710B

KW - Alzheimer's disease

KW - Amyloids

KW - Cognitive deficits

KW - Disease modification

KW - M1 muscarinic acetylcholine receptor

KW - Memory

KW - Neuroinflammation

KW - Tau protein

KW - σ1 receptor

UR - http://www.scopus.com/inward/record.url?scp=84958057736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958057736&partnerID=8YFLogxK

U2 - 10.1159/000440864

DO - 10.1159/000440864

M3 - Article

C2 - 26606130

AN - SCOPUS:84958057736

VL - 16

SP - 95

EP - 110

JO - Neurodegenerative Diseases

JF - Neurodegenerative Diseases

SN - 1660-2854

IS - 1-2

ER -